Board Appointment

RNS Number : 4827Y

Genedrive PLC

22 August 2018

 

For release: 22 August 2018

genedrive plc ("genedrive" or the "Company")

genedrive appoints Chris Yates as Non-Executive Director

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces that it has appointed Chris Yates as Non-Executive Director with immediate effect.

Chris co-founded diagnostics group Abingdon Health in 2008 and, after initially serving as a non-executive director, he has been Abingdon's CEO since July 2015.  Chris has over 20 years' experience of working in listed company environments. Prior to Abingdon, he was CFO of AIM-listed Immunodiagnostic Systems Holdings PLC and Cozart plc.  Chris is a Chartered Accountant and has a degree in economics from the University of Cambridge.

Ian Gilham, Non-Executive Chairman of genedrive, said: "Chris has strong experience in diagnostics businesses as well a deep understanding of the AIM market.  We look forward to working with him in the next phase of the Company's growth."

Chris Yates said: "I am excited to join the Board at what is a very exciting and critical stage of the growth of the company.  The diagnostics market is a large and attractive marketplace and the Company appears well placed to exploit the potential of the Genedrive® system."

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Full name and age: Chris Henry Francis Yates (aged 44)

Chris Yates does not currently hold any shares in genedrive plc.

Current Directorships or Partnerships:

Abingdon Health Limited

Forsite Diagnostics Limited

Serascience Limited

Previous Directorships or Partnerships:

Bioscience Ventures Limited

Immunodiagnistic Systems Limited

Immunodiagnostic Systems Holdings plc

DiaMetra S.r.l.

Immunodiagnostic Systems France SAS

Immunodiagnostic Systems Deutchland GmbH

Immunodiagnostic Systems Inc

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.

-  Ends  -

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                              [phone]

Matthew Fowler: CFO

Peel Hunt LLP

James Steel                                                                                                                       [phone]

Oliver Jackson

Stanford Capital

Patrick Claridge                                                                                                                 [phone]

Consilium Strategic Communications

Chris Gardner                                                                                                                    [phone]

Matthew Neal

Laura Thornton

[e-mail] 

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF assay has been launched in India and a Genedrive® HCV test has received CE-IVD Certification and has been launched in Africa. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and Asia Pacific regions, and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV ID Kit and Genedrive® platform in India.

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

 

END

 

 

BOAUAVVRWKAWUAR